Telitacicept 
RemeGen
['telitacicept']
patients with #sle achieved sri-4 more often on the dual blys and april inhibitor telitacicept than with placebo in a phase 3 trial from china. #eular2023 
The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders